EGCG suppresses prostate cancer cell growth modulating acetylation of androgen receptor by anti-histone acetyltransferase activity

Yoon, Ho‐Geun

doi:10.3892/ijmm.2012.966

Cited by 62 publications

(37 citation statements)

References 18 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The HDAC or HAT inhibitory activity of EGCG has been shown to lead to hyper- or hypo-acetylation of non-histone proteins such as p53, p65, androgen and estrogen receptors [52, 54–56]. Even though in our study p65 acetylation was not diminished by EGCG (data not shown) as demonstrated previously [52], we found that EGCG can reduce the binding of p65 and p300 to the promoter region of NF-κB-regulated genes with an increased recruitment of HDAC1/2.…”

Section: Discussionmentioning

confidence: 99%

EGCG prevents PCB-126-induced endothelial cell inflammation via epigenetic modifications of NF-κB target genes in human endothelial cells

Liu

Perkins

Hennig

2016

The Journal of Nutritional Biochemistry

View full text Add to dashboard Cite

Anti-inflammatory polyphenols, such as epigallocatechin-3-gallate (EGCG), have been shown to protect against the toxicity of environmental pollutants. It is well known that bioactive food compounds such as polyphenols may exert their protection by modulating inflammatory pathways regulated through nuclear factor-kappa B (NF-κB) signaling. EGCG has been reported to inhibit NF-κB activation. We hypothesize that EGCG can protect against PCB-induced endothelial inflammation in part through epigenetic regulation of NF-kB-regulated inflammatory genes. In order to test this hypothesis, human endothelial cells (EA.hy926) were exposed to physiologically relevant levels of coplanar PCB 126 and/or 15 or 30 μM of EGCG, followed by quantification of NF-kB subunit p65, histone acetyltransferase (HAT) p300 and histone deacetylases (HDACs) accumulation through ChIP assay in the promotor region of inflammatory genes. In addition, the enrichment of the acetylated H3 (ac-H3) was also quantified. PCB 126 exposure increased the expression of vascular inflammatory mediators, including interleukin (IL)-6, C-reactive protein (CRP), intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and IL-1α/β, which were prevented by pre-treatment with EGCG. This inhibitory effect by EGCG correlated with abolished nuclear import of p65, decreased chromatin binding of p65 and p300, as well as increased chromatin binding of HDAC1/2. Furthermore, EGCG induced hypo-acetylation of H3, which accounts for deactivation of downstream genes. These data suggest that EGCG-induced epigenetic modifications can decrease PCB-induced vascular toxicity.

show abstract

Section: Discussionmentioning

confidence: 99%

EGCG prevents PCB-126-induced endothelial cell inflammation via epigenetic modifications of NF-κB target genes in human endothelial cells

Liu

Perkins

Hennig

2016

The Journal of Nutritional Biochemistry

View full text Add to dashboard Cite

show abstract

“…Thus, agents or natural products that target those enzymes may also interfere with nuclear translocation of AR and indirectly inhibit AR mediated gene expression. For instance, the green tea derived EGCG, has been demonstrated to inhibit acetyltransferase activity up to 80% when used at a concentration of 25 µM [100]. Treatment with EGCG resulted in reduced AR acetylation and impeded androgen-mediated nuclear translocation of AR in PCa cell lines [100].…”

Section: Natural Products Against Pcamentioning

confidence: 99%

“…For instance, the green tea derived EGCG, has been demonstrated to inhibit acetyltransferase activity up to 80% when used at a concentration of 25 µM [100]. Treatment with EGCG resulted in reduced AR acetylation and impeded androgen-mediated nuclear translocation of AR in PCa cell lines [100]. These effects were confirmed in vivo using a PCa xenograft model [34].…”

Section: Natural Products Against Pcamentioning

confidence: 99%

Bioactive natural products for chemoprevention and treatment of castration-resistant prostate cancer

Kallifatidis

Hoy

Lokeshwar

2016

Seminars in Cancer Biology

View full text Add to dashboard Cite

Prostate cancer (PCa), a hormonally-driven cancer, ranks first in incidence and second in cancer related mortality in men in most Western industrialized countries. Androgen and androgen receptor (AR) are the dominant modulators of PCa growth. Over the last two decades multiple advancements in screening, treatment, surveillance and palliative care of PCa have significantly increased quality of life and survival following diagnosis. However, over 20% of patients initially diagnosed with PCa still develop an aggressive and treatment-refractory disease. Prevention or treatment for hormone-refractory PCa using bioactive compounds from marine sponges, mushrooms, and edible plants either as single agents or as adjuvants to existing therapy, has not been clinically successful. Major advancements have been made in the identification, testing and modification of the existing molecular structures of natural products. Additionally, conjugation of these compounds to novel matrices has enhanced their bio-availability; a big step towards bringing natural products to clinical trials. Natural products derived from edible plants (nutraceuticals), and common folk-medicines might offer advantages over synthetic compounds due to their broader range of targets, as compared to mostly single target synthetic anticancer compounds; e.g. kinase inhibitors. The use of synthetic inhibitors or antibodies that target a single aberrant molecule in cancer cells might be in part responsible for emergence of treatment refractory cancers. Nutraceuticals that target AR signaling (epigallocatechin gallate [EGCG], curcumin, and 5α-reductase inhibitors), AR synthesis (ericifolin, capsaicin and others) or AR degradation (betulinic acid, di-indolyl diamine, sulphoraphane, silibinin and others) are prime candidates for use as adjuvant or mono-therapies. Nutraceuticals target multiple pathophysiological mechanisms involved during cancer development and progression and thus have potential to simultaneously inhibit both prostate cancer growth and metastatic progression (e.g., inhibition of angiogenesis, epithelial-mesenchymal transition (EMT) and proliferation). Given their multi-targeting properties along with relatively lower systemic toxicity, these compounds offer significant therapeutic advantages for prevention and treatment of PCa. This review emphasizes the potential application of some of the well-researched natural compounds that target AR for prevention and therapy of PCa.

show abstract

“…EGCG acted at multiple levels including inhibiting interdomain N-C termini interaction, repressing the prostate cancer related mutant T877A and eventually inhibiting cancer cell growth. Lee et al [60] obtained similar results using a prostate cancer cell line in response to GT catechins. The researchers proposed that catechins modulated AR acetylation was modulated in the presence of GT catechins thereby inhibiting the translocation of the AR protein to the nucleus.…”

Section: Cancermentioning

confidence: 62%

Green Tea as an Agricultural Based Health Promoting Food: The Past Five to Ten Years

Shi

Schlegel

2012

Agriculture

View full text Add to dashboard Cite

Abstract:The consumption of tea originated in ancient China over 4000 years ago and is currently the second most popular beverage in the world after water. Tea is an aromatic beverage prepared by pouring hot water over cured leaves of the Camellia sinensis plant. The link between tea intake, most notably green tea, and health has resulted in intense research on the components responsible for preventing the onset of several chronic diseases, including atherosclerosis, cancer, obesity and diabetes. In particular, the high levels of chemically diverse phenols (e.g., phenolic acids, flavonoids) present in tea exhibit potent protective properties against many of these diseases. Although health related research on green tea and its predominant phenol (catechins) has been on-going for decades, major advances have occurred in the last 5-10 years. Therefore, this review focuses on seminal studies reported primarily within the last five years but not extending past ten years on the link between health and green tea with an emphasis on the catechins.

show abstract

EGCG suppresses prostate cancer cell growth modulating acetylation of androgen receptor by anti-histone acetyltransferase activity

Cited by 62 publications

References 18 publications

EGCG prevents PCB-126-induced endothelial cell inflammation via epigenetic modifications of NF-κB target genes in human endothelial cells

EGCG prevents PCB-126-induced endothelial cell inflammation via epigenetic modifications of NF-κB target genes in human endothelial cells

Bioactive natural products for chemoprevention and treatment of castration-resistant prostate cancer

Green Tea as an Agricultural Based Health Promoting Food: The Past Five to Ten Years

Contact Info

Product

Resources

About